Safinamide

Chemical formula: C₁₇H₁₉FN₂O₂  Molecular mass: 302.349 g/mol  PubChem compound: 131682

Therapeutic indications

Safinamide is indicated for:

Parkinson's disease

Population group: only adults (18 years old or older)

Safinamide is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as addon therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Safinamide is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Pethidine

Pethidine

Albinism, retinal degeneration, uveitis, retinopathy

at least one of
Albinism
Degeneration of retina
Uveitis
Retinal disorder

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: XADAGO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈